Effects of Melatonin and Rilmazafone on Nocturia in the Elderly
|
|
- Kellie Stevenson
- 6 years ago
- Views:
Transcription
1 The Journal of International Medical Research 2007; 35: Effects of Melatonin and Rilmazafone on Nocturia in the Elderly K SUGAYA, S NISHIJIMA, M MIYAZATO, K KADEKAWA AND Y OGAWA Division of Urology, Department of Organ-oriented Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan We compared the effects of melatonin, an antioxidant and sleep inducer in humans, and rilmazafone hydrochloride, a hypnotic, in elderly patients with nocturia. Patients received either melatonin (2 mg/day; n = 20) or rilmazafone (2 mg/day; n = 22) for 4 weeks. There were no significant differences in the mean age, the quality of life (QoL) score and the serum melatonin levels between the two groups at baseline. After 4 weeks treatment, the number of nocturnal urinations was significantly decreased and the QoL score was significantly improved in both groups. There was no significant difference between the patientreported effectiveness ratings between the two groups. The serum melatonin level was significantly increased in the melatonin-treated group, but it remained unchanged in the rilmazafone-treated group. Melatonin and rilmazafone were equally effective for nocturia in the elderly. We recommend that the problems of sleep disturbance should be considered when choosing a therapy for nocturia. KEY WORDS: RILMAZAFONE; HYPNOTIC; NOCTURIA; ELDERLY PATIENTS; MELATONIN; SLEEP DISTURBANCE; QUALITY OF LIFE Introduction Nocturnal urinary frequency is a common symptom in the elderly and one of the most bothersome urological symptoms. 1 Nocturia means that an individual has to wake once or more at night to void 2 and it may result in sleep disturbance leading to daytime fatigue as well as an impaired quality of life (QoL). 1,3 Patients are often uncertain, however, whether nocturia is the cause of their sleep disturbance or whether sleep disturbance leads to nocturia. 4 In patients with nocturia, the hypnotic agent, rilmazafone hydrochloride, may decrease nocturnal frequency. 4 Minor tranquilizers are especially effective for controlling nocturia in patients with low levels of human atrial natriuretic peptide (HANP). 5 In our previous study, the serum melatonin level was found to be very low in patients with nocturia compared with those patients without nocturia. 6 Moreover, the level was lower in patients with bothersome nocturia compared with patients without this condition. 7 It has also been reported that melatonin is effective for nocturia in patients with benign prostatic enlargement. 8 Melatonin is an antioxidant and sleep inducer in humans 9 and is available as a supplement in many countries. We therefore compared the effects of melatonin and the hypnotic, rilmazafone, on nocturia in elderly 685
2 patients. We also measured serum melatonin levels before and after treatment. Patients and methods STUDY POPULATION The subjects were selected from outpatients who consulted the Department of Urology at our University Hospital (University of the Ryukyus, Okinawa, Japan) or one of our affiliated hospitals between January 2005 and February Patients who met the following criteria were enrolled: (i) their lower urinary tract symptoms (except for nocturia) were already being controlled by medication (adrenergic α-1 receptor antagonists, antimuscarinic agents and/or herbal medicines) for a period of at least 2 months; (ii) they had nocturia that was bothersome and urinated at least twice during their sleeping period; (iii) they did not have a high fluid intake for health reasons and they were being careful to avoid excessive intake because it could cause nocturia; 10 (iv) they did not have neurological or psychological abnormalities, hepatic dysfunction, renal dysfunction, diabetes mellitus, or cardiovascular disease; (v) they were not taking tranquillizers, hypnotics or melatonin; and (vi) they were not performing regular physical exercise (walking has been shown to decrease nocturnal frequency). 11 Patients with bacterial cystitis, bacterial prostatitis or urinary tract cancer were excluded. STUDY METHODS The patients were randomly divided into two groups; one group received melatonin (2 mg/day) and the other group received rilmazafone hydrochloride (2 mg/day) for 4 weeks. Patients in both groups took their medication just before going to bed. This study was unblinded, hence patients knew which medicine they were using. We examined the mean number of daytime and nocturnal (during the sleeping period) urinations over 4 weeks, the QoL score using the International Prostatic Symptom Score (happy, 0; satisfied, 1; almost satisfied, 2; not satisfied/not dissatisfied, 3; slightly dissatisfied, 4; dissatisfied, 5; and unhappy, 6), 12 and the perception of nocturnal urination (not bothersome, slightly bothersome, bothersome, or very bothersome) before and after 4 weeks of treatment. Subjects who reported that nocturnal urination was not bothersome or only slightly bothersome were assigned to the non-bothersome category, while subjects who stated that it was bothersome or very bothersome were assigned to the bothersome category. We also examined the side effects of these agents and whether the subjects would like to continue treatment with melatonin or rilmazafone. Blood samples were taken from all subjects at 10:00 12:00 h at baseline and again after 4 weeks of melatonin or rilmazafone therapy for measurement. Serum melatonin, plasma HANP and brain natriuretic peptide (BNP) levels were measured by radioimmunoassay, and compared before and after treatment. This study was performed after obtaining approval from the Ethics Committee of the Faculty of Medicine, University of the Ryukyus, Japan, and all patients entered provided written informed consent to participate. STATISTICAL ANALYSIS Results are reported as the mean ± SD. Student s t-test for paired or unpaired data was used for the statistical analyses. A P-value < 0.05 was considered to be statistically significant. Differences between categorical variables were assessed with the χ 2 test. 686
3 Results A total of 42 patients (25 men and 17 women, aged years) were enrolled in this study. All 25 male patients had benign prostatic enlargement with or without an overactive bladder, while 10 female patients had urethral syndrome and/or an overactive bladder. The remaining seven female patients only had nocturia. The residual urine volume of each patient was < 20 ml on abdominal ultrasonography. A total of 20 patients (13 men and seven women, aged 73 ± 7 years old) were randomly assigned to the melatonin group; and 22 patients (12 men and 10 women, aged 71 ± 8 years old) were randomly assigned to the rilmazafone group. All male patients were being treated with α-1 receptor antagonists (tamsulosin or naftopidil) and an anticholinergic agent (propiverine hydrochloride). All female patients were receiving an anticholinergic agent (propiverine hydrochloride). Five female patients from each group had taken herbal medicines for at least 8 weeks before the start of this study. These medications were continued during the present study. There were no significant differences in age, QoL score, serum melatonin level, and plasma HANP and BNP levels between the two groups at baseline (Table 1). At the start of the study, all patients considered their nocturnal urination to be bothersome. In both the melatonin- and rilmazafonetreated groups, the mean number of nocturnal urinations was significantly decreased (P < 0.001) after 4 weeks compared with baseline (Tables 1 and 2, Fig. 1). The mean number of daytime urinations, however, was unchanged. The mean QoL score was significantly improved in both groups (melatonin, P = 0.004; rilmazafone, P < 0.001) compared with baseline. The mean serum melatonin level in the melatonin-treated group was significantly increased (P < 0.001) after 4 weeks of melatonin administration, however, the mean level in the rilmazafone-treated group did not change after 4 weeks of rilmazafone administration (Tables 1 and 2). There was no change in the HANP and BNP levels following administration of either melatonin or rilmazafone. With regard to patients impression of the effectiveness of the study medication, seven TABLE 1: Baseline characteristics of patients with nocturia randomly assigned to receive either melatonin (2 mg/day) or rilmazafone (2 mg/day) for 4 weeks Melatonin Rilmazafone (n = 20) (n = 22) Male:female ratio 13:7 12:10 Age (years) 73 ± 7 71 ± 8 Number of daytime urinations 8.1 ± ± 1.3 Number of nocturnal urinations 3.4 ± ± 0.9 QoL score 4.7 ± ± 0.6 Serum melatonin level (pg/ml) 5.6 ± ± 3.0 Plasma HANP level (pg/ml) 22 ± ± 17 Plasma BNP level (pg/ml) 27 ± ± 15 Values are mean ± SD. QoL, quality of life (International Prostatic Symptom Score. 0, happy; 6, unhappy); 12 HANP, human atrial natriuretic peptide; BNP, brain natriuretic peptide. 687
4 TABLE 2: Patient characteristics after 4 weeks of treatment with either melatonin (2 mg/day) or rilmazafone (2 mg/day) Melatonin Rilmazafone (n = 20) (n = 22) No. of daytime urinations 7.9 ± ± 1.2 No. of nocturnal urinations 2.6 ± 0.9*** 2.5 ± 1.1*** QoL score 4.0 ± 0.8** 3.9 ± 0.7*** Serum melatonin level (pg/ml) 87.2 ± 71.7***,b 6.4 ± 4.9 b Plasma HANP level (pg/ml) 24 ± ± 18 Plasma BNP level (pg/ml) 29 ± ± 15 Non-bothersome nocturia 14 (70) 11 (50) Occurrence of side effects 1 (5) 2 (9) Patient s treatment effectiveness rating: Excellent 2 (10) 4 (18) Good 5 (25) 6 (27) Fair 9 (45) 4 (18) No change 4 (20) 8 (36) Willingness to continue with the same treatment 12 (60) a 6 (27) a Values are mean ± SD or number of patients (%). **P < 0.01 (P = 0.004), ***P < compared with baseline; a P < 0.05 (P = 0.032), b P < 0.01 between the two groups. QoL, quality of life (International Prostatic Symptom Score. 0, happy; 6, unhappy); 12 HANP, human atrial natriuretic peptide: BNP, brain natriuretic peptide. 5 *** *** Melatonin Rilmazafone Number of nocturnal urinations Before After administration of melatonin or rilmazafone FIGURE 1: Mean number (±SD) of nocturnal urinations before and after 4 weeks administration of melatonin (2 mg/day) or rilmazafone (2 mg/day) ***P <
5 patients (35%) in the melatonin-treated group rated the treatment as either excellent or good and nine (45%) rated it as fair (Table 2). In the rilmazafone-treated group, an excellent or good rating was reported by 10 (45%) patients and a fair rating by four (18%). There was no significant difference between the effectiveness ratings between the two groups. Before administration of melatonin or rilmazafone, all patients considered their nocturia to be bothersome. After 4 weeks of treatment, 14 (70%) patients from the melatonin-treated group and 11 (50%) patients from the rilmazafone-treated group considered their nocturia to be no longer bothersome. In one (5%) patient from the melatonintreated group and two (9%) from the rilmazafone-treated group an unsteady feeling was sometimes noted when they woke at night to urinate, however these side effects were slight and the patients continued with the study treatment for 4 weeks. After administration for 4 weeks, 12 (60%) patients in the melatonin-treated group wanted to continue therapy. This number was significantly larger than the six patients (27%) who wanted to continue rilmazafone therapy (P = 0.032). The reason for not wanting to continue therapy with either melatonin or rilmazafone was little or no effectiveness in eight (40%) patients from the melatonin-treated group and 10 (45%) patients from the rilmazafone-treated group. In eight (36%) patients from the rilmazafone-treated group, the fear of becoming unable to sleep without hypnotics was a reason for not wishing to continue with the medication. The three patients who had noted unsteadiness when they woke at night to urinate reported this as a reason for not wishing to continue with the medication. Discussion In the present study, we compared the effectiveness of melatonin and rilmazafone hydrochloride in nocturia. In elderly patients who did not have an excessive intake of water and whose plasma natriuretic peptide levels were not very high, the efficacy of melatonin was almost equal to that of rilmazafone. The percentage of patients who assigned an excellent or good rating was, however, larger in the rilmazafone-treated group and the percentage that assigned a rating of fair or better was larger in the melatonin-treated group, although there was no significant difference between the two groups. The percentage of patients who came to consider nocturia as nonbothersome was larger (not statistically significant) in the melatonin-treated group and a significantly higher percentage of patients given melatonin hoped to continue with it compared with those given rilmazafone. Although the patients were randomly divided into the two groups, the study was unblinded and the patients knew which medicine they were using. Few patients were concerned about using melatonin, probably because it is available as a supplement, but several patients were concerned about using rilmazafone because they were worried about the potential risk of becoming dependent on hypnotics. Hypnotics have been reported to be useful for treating nocturia. 4,5,13,14 Fujikawa et al. 5 reported that minor tranquillizers are especially effective for controlling nocturia in patients with low HANP levels. It has also been reported that patients taking nitrazepam (a medium-acting hypnotic) have less difficulty returning to sleep compared with those who take triazolam (an ultra-short acting hypnotic), and that nitrazepam may be more appropriate for 689
6 elderly patients who awaken because of nocturia. 13 Some patients, however, refuse to use hypnotics due to their fear of becoming dependent, even though they have insomnia. Sleep disorders can cause nocturia, while nocturia is one of the most bothersome urological symptoms and also results in sleep disturbance. 1,3,15 It is, therefore, common for patients to be uncertain whether nocturia is the cause of their sleep disturbance or if it is the sleep disturbance that leads to nocturia and for these patients, rilmazafone, a mediumacting hypnotic, has been shown to be effective. 4 Melatonin is produced by the pineal gland and is one of the strongest natural antioxidants; it is also closely involved in the timing of sleep in humans. 9,16 18 In our previous study, the night-time serum melatonin level was significantly lower in elderly persons than younger persons, and the serum melatonin level of elderly persons with nocturia was lower than that of elderly persons without nocturia. 6 Moreover, we found a significant correlation between daytime and night-time serum melatonin levels. 19 Administration of melatonin was reported safely to improve nocturia in patients with bladder outlet obstruction, 8 while treatment with melatonin (3 mg/day) for up to 6 months improved sleep quality and decreased sleep onset latency in patients with insomnia. 20 In the present study, the serum melatonin level was increased by administration of melatonin (2 mg/day), but not by rilmazafone (2 mg/day), suggesting that the decrease of nocturnal urination after treatment with rilmazafone did not depend on the serum melatonin level. This suggests that monitoring the levels of melatonin is probably not important in patients with nocturia. Melatonin and rilmazafone appear to have different mechanisms of action, however they were both found to be effective for treating nocturia in the elderly. We suggest, therefore, that when choosing a therapy for nocturia, physicians not only consider lower urinary tract function but also sleep disturbance. Acknowledgements This study was supported by a research grant (H16-Choju-008) for Comprehensive Research on Aging and Health from the Japanese Ministry of Health, Labour and Welfare, and a 2005 grant from the Mitsui Sumitomo Insurance Welfare Foundation of Japan. Conflicts of interest No conflicts of interest were declared in relation to this paper. Received for publication 10 May 2007 Accepted subject to revision 16 May 2007 Revised accepted 1 August 2007 Copyright 2007 Field House Publishing LLP References 1 Blanker MH, Bohnen AM, Groeneveld FP, et al: Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol 2000; 164: Abrams P, Cardozo L, Fall M, et al: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: Asplund R: Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999; 84: Sugaya K: Pharmacological evaluation of rilmazafone hydrochloride in urological clinics: Effect of rilmazafone hydrochloride on nocturia. Pharma Medica 1991; 9: Fujikawa K, Kasahara M, Matsui Y, et al: 690
7 Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. Scand J Urol Nephrol : Sugaya K, Nishijima S, Oda M, et al: Biochemical analysis of nocturia in the elderly. Neurourol Urodyn : Nishijima S, Sugaya K, Owan T, et al: Study of factors related to non-bothersome nocturnal urination. Nippon Hinyokika Gakkai Zasshi 2007; 98: Drake MJ, Mills IW, Noble JG: Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 2004; 171: Brzezinski A: Mechanisms of disease: melatonin in humans. N Engl J Med 1997; 336: Sugaya K, Nishijima S, Oda M, et al: Change of blood viscosity and urinary frequency by high water intake. Int J Urol 2007; 14: Sugaya K, Nishijima S, Owan T, et al: Effects of walking exercise on nocturia in the elderly. Biomed Res 2007; 28: Cockett ATK, Khoury S, Aso Y, et al: In: Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (Cockett ATK, Khoury S, Aso Y, et al, eds). Channel Islands: Scientific Communication International, 1994; pp Takami N, Okada A: Triazolam and nitrazepam use in elderly outpatients. Ann Pharmacother 1993; 27: Marschall-Kehrel D: Update on nocturia: the best of rest is sleep. Urology 2004; 64: Weiss JP, Blaivas JG: Nocturia. J Urol 2000; 163: Dijk DJ, Cajochen C: Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms 1997; 12: Zhdanova IV, Tucci V: Melatonin, circadian rhythms, and sleep. Curr Treat Options Neurol 2003; 5: Zhdanova IV: Melatonin as a hypnotic: pro. Sleep Med Rev 2005; 9: Sugaya K, Nishijima S, Oda M, et al: Biochemical and body composition analysis of nocturia in the elderly. Neurourol Urodyn in press. 20 Siegrist C, Benedetti C, Orlando A, et al: Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 2001; 30: Author s address for correspondence Dr Kimio Sugaya Division of Urology, Department of Organ-oriented Medicine, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa , Japan. sugaya@med.u-ryukyu.ac.jp 691
Citation The Journal of urology (2010), 184( Right Research, Inc. Published by Elsevie
Title Efficacy of nondrug lifestyle measu nocturia. Author(s) Soda, Takeshi; Masui, Kimihiko; Oku Ogawa, Osamu; Yoshimura, Koji Citation The Journal of urology (2010), 184( Issue Date 2010-09 URL http://hdl.handle.net/2433/129437
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationORIGINAL ARTICLE. Key words benign prostatic hyperplasia, bother, lower urinary tract symptoms, quality of life, tamsulosin
LUTS (2012) 4, 45 50 ORIGINAL ARTICLE Correlations among Lower Urinary Tract Symptoms, Bother, and Quality of Life in Patients with Benign Prostatic Hyperplasia and Associated Fluctuations with Tamsulosin
More informationGuidance on water intake effectively improves urinary frequency in patients with nocturia
bs_bs_banner International Journal of Urology (214) 21, 595 6 doi: 1.1111/iju.12387 Original Article: Clinical Investigation Guidance on water intake effectively improves urinary frequency in patients
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationPrevalence, Incidence, and Resolution of Nocturnal Polyuria in a Longitudinal Community-based Study in Older Men: The Krimpen Study
EUROPEAN UROLOGY 63 (2013) 542 547 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Aging Male Editorial by Stephan Madersbacher and Jean-Nicolas Cornu on
More informationCHAPTER 6. M.D. Eckhardt, G.E.P.M. van Venrooij, T.A. Boon. hoofdstuk :49 Pagina 89
hoofdstuk 06 19-12-2001 09:49 Pagina 89 Urethral Resistance Factor (URA) Versus Schäfer s Obstruction Grade and Abrams-Griffiths (AG) Number in the Diagnosis of Obstructive Benign Prostatic Hyperplasia
More informationAdrenoceptor Antagonist Tamsulosin for the Treatment of Voiding Symptoms Improves Nocturia and Sleep Quality in Women. The α 1 FEMALE UROLOGY
The α 1 Adrenoceptor Antagonist Tamsulosin for the Treatment of Voiding Symptoms Improves Nocturia and Sleep Quality in Women Sun-Ouck Kim, Hyang Sik Choi, Dongdeuk Kwon FEMALE UROLOGY Department of Urology,
More informationStrong Impact of Nocturia on Sleep Quality in Patients with Lower Urinary Tract Symptoms
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2012 August 30(2): 123-130 http://dx.doi.org/10.5534/wjmh.2012.30.2.123 Original Article Strong Impact of Nocturia on Sleep Quality in Patients with
More informationSeung Whan DOO, Jae Heon KIM, Won Jae YANG, and Yun Seob SONG
LUTS (13) 5, 13 139 ORIGINAL ARTICLE Is There Any Objective Improvement of Nocturia by Combination Treatment of Zolpidem and Alpha-Blocker Therapy for Unresponsive to Alpha-Blocker Monotherapy in Men with
More informationNight-time visits to the toilet?
Engelska/English Night-time visits to the toilet? Facts about NOCTURIA - waking up at night to go to the toilet Facts about nocturia What is nocturia? Causes of nocturia Helpful advice and precautions
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationHEALTH AND WELLBEING IMPACT AND TREATMENT OF NOCTURIA A REVIEW OF THE LITERATURE
HEALTH AND WELLBEING IMPACT AND TREATMENT OF NOCTURIA A REVIEW OF THE LITERATURE Nadir I. Osman, 1 Christopher Hillary, 1 *Christopher R. Chapple 2 1. Clinical Research Fellow, Department of Urology, Royal
More informationA SURVEY ON LOWER URINARY TRACT SYMPTOMS (LUTS) AMONG PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) IN HOSPITAL UNIVERSITI SAINS MALAYSIA (HUSM)
Malaysian Journal of Medical Sciences, Vol. 14, No. 2, July 2007 (67-71) SHORT COMMUNICATION A SURVEY ON LOWER URINARY TRACT SYMPTOMS (LUTS) AMONG PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) IN HOSPITAL
More informationNOCTIVA (desmopressin acetate) nasal spray
NOCTIVA (desmopressin acetate) nasal spray Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationNOCTIVA (desmopressin acetate) nasal spray
NOCTIVA (desmopressin acetate) nasal spray Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationNOCTURIA WHAT S KEEPING YOU UP AT NIGHT? Frances Stewart RN,NCA
WHAT S KEEPING YOU UP AT NIGHT? Frances Stewart RN,NCA Objectives Be more knowledgeable in the diagnosis and treatment of nocturia Differentiate between urological causes of nocturia Select appropriate
More informationINJINTERNATIONAL. The Prevalence of Nocturia and Nocturnal Polyuria: Can New Cutoff Values Be Suggested According to Age and Sex?
Official Journal of Korean Continence Society / Korean Society of Urological Research / The Korean Children s Continence and Enuresis Society / The Korean Association of Urogenital Tract Infection and
More informationMichael Organ PGY2 Urology Major Presentation 2011
Michael Organ PGY2 Urology Major Presentation 2011 1 Epidemiology Pathophysiology Evaluation and Diagnosis Treatments -General -Nocturnal Polyuria -BPH -OAB Conclusion 2 Nocturia is the complaint that
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationThe 24-h frequency-volume chart in adults reporting no voiding complaints: defining reference values and analysing variables
Original Article THE FVC IN ADULTS E.P. VAN HAARST et al. The 24-h frequency-volume chart in adults reporting no voiding complaints: defining reference values and analysing variables E.P. VAN HAARST*,
More informationNaoki Wada, Seiji Matsumoto, Masafumi Kita, Kazumi Hashizume and Hidehiro Kakizaki
bs_bs_banner International Journal of Urology (1) 1, 15 1 doi: 1.1111/iju.157 Original Article: Clinical Investigation Decreased urinary nerve growth factor reflects prostatic volume reduction and relief
More informationThe standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society
Blackwell Science, LtdOxford, UK BJUBJU International1465-5101BJU International 90Supplement 3December 2002 147 STANDARDIZATION OF TERMINOLOGY P. VAN KERREBROECK et al. 10.1046/j.1464-4096.2002.147.x Original
More informationWhat is Nocturia? What are the Consequences of Nocturia? 23/10/12. Dr. Tam Cheuk Kwan Consultant, Dept. of M&G Tuen Mun Hospital
Survival 23/10/12 Dr. Tam Cheuk Kwan Consultant, Dept. of M&G Tuen Mun Hospital What is Nocturia? Nocturia is the complaint that the individual has to wake at night one or more times to void. (ICS definition
More informationINVESTIGATION OF LOWER URINARY TRACT SYMPTOMS IN UROLOGICAL OUTPATIENTS USING ORIGINAL IPSS PLUS POST MICTURITION DRIBBLE QUESTIONNAIRE
INVESTIGATION OF LOWER URINARY TRACT SYMPTOMS IN UROLOGICAL OUTPATIENTS USING ORIGINAL IPSS PLUS POST MICTURITION DRIBBLE QUESTIONNAIRE Tadashi Hanail*, Seiji Matsumotol*, Nobutaka Shimizu, Hirotsugu Uemural
More informationSex Hormones, Diuresis, LUTS, nocturia an Enigma in the Menopause? Prof Dr Karel Everaert NOPIA Research Group and INPRG Gent, Belgium
Sex Hormones, Diuresis, LUTS, nocturia an Enigma in the Menopause? Prof Dr Karel Everaert NOPIA Research Group and INPRG Gent, Belgium Conflicts of Interest Personal: P2Solutions (smart textile applications)
More informationChanges in Nocturia after Photoselective Vaporization of the Prostate for Patients with Benign Prostatic Hyperplasia
www.kjurology.org DOI:10.4111/kju.2010.51.8.531 Voiding Dysfunction Changes in Nocturia after Photoselective Vaporization of the Prostate for Patients with Benign Prostatic Hyperplasia Chang Ju Lee, Min
More informationAriana L. Smith and Alan J. Wein Division of Urology, Hospital of University of Pennsylvania, Philadelphia, PA, USA
; 2011 Mini Reviews PHARMACOLOGICAL MANAGEMENT OF NOCTURIA SMITH and WEIN BJUI Outcomes of pharmacological management of with non-antidiuretic agents: does statistically significant equal clinically significant?
More informationThe patient, your co-pilot in assessing LUTS
The patient, your co-pilot in assessing LUTS Frank Van der Aa Leuven, Belgium This symposium is supported by Astellas Pharma Europe Ltd., including speaker honoraria and production of materials the slides
More informationThe ICS- BPH Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction
British Journal of Urology (1998), 82, 619 623 The ICS- BPH Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction J.M. REYNARD1, Q. YANG2, J.L. DONOVAN3,T.J. PETERS3, W. SCHAFER4,
More informationCLINICIAN INTERVIEW SPECIFIC FACTORS OF NOCTURIA: A SPECIALIST PERSPECTIVE. An interview with Eric S. Rovner, MD
SPECIFIC FACTORS OF NOCTURIA: A SPECIALIST PERSPECTIVE An interview with Eric S. Rovner, MD Eric S. Rovner, MD, is Associate Professor of Urology at the Medical University of South Carolina in Charleston.
More informationMystery about Nocturia Anything we can do?
Mystery about Nocturia Anything we can do? 2016 Annual Scientific Meeting Hong Kong Continence Society 8th October 2016 Dr. Wong Kwok Keung William Associate Consultant Department of M&G/KWH No Disclaimer
More informationPREVALENCE AND RISK FACTORS OF NOCTURIA AND QUALITY OF LIFE OF NOCTURIA SUBJECTS FROM SHANGHAI
Acta Medica Mediterranea, 2014, 30: 1103 PREVALENCE AND RISK FACTORS OF NOCTURIA AND QUALITY OF LIFE OF NOCTURIA SUBJECTS FROM SHANGHAI LEI WANG 1#, BO LIU 2#, SHENGSONG HUANG 2, QIANG WU 2, DENGLONG WU
More informationAdditional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
Original Article - Female Urology Investig Clin Urol Posted online 217.6.27 Posted online 217.6.27 pissn 2466-493 eissn 2466-54X Additional low-dose antimuscarinics can improve overactive bladder symptoms
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationAssociation of BPH with OAB: The Plumbing or the Pump?
Association of BPH with OAB: The Plumbing or the Pump? Ryan P. Terlecki, MD FACS Associate Professor of Urology Director, Men s Health Clinic Director, GURS Fellowship in Reconstructive Urology, Prosthetic
More informationIncontinence: The silent scourge of the young and old. The International Continence Society has. In this article:
Focus on CME at the University of Toronto Incontinence: The silent scourge of the young and old By Sender Herschorn, BSc, MDCM, FRCSC In this article: 1. What is the workup for urinary incontinence? 2.
More informationPractical approaches to diagnosis and management of nocturia
UROLOGY 7 Practical approaches to diagnosis and management of nocturia JONATHAN REES, MIKE KIRBY, ANN WILLIAMS, LEONARD HIRSCH AND NIKHIL CHOPRA Nocturia is an under-reported and undertreated condition
More informationShrestha A, Chalise PR, Sharma UK, Gyawali PR, Shrestha GK, Joshi BR. Department of Surgery, TU Teaching Hospital, Maharajgunj, Kathmandu, Nepal
Original Article Intravesical Prostatic Protrusion is better than Prostate Volume in Predicting Symptom Severity in Benign Prostatic Hyperplasia: A Prospective Clinical Study Shrestha A, Chalise PR, Sharma
More informationImpact of urethral catheterization on uroflow during pressure-flow study
Research Report Impact of urethral catheterization on uroflow during pressure-flow study Journal of International Medical Research 2016, Vol. 44(5) 1034 1039! The Author(s) 2016 Reprints and permissions:
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationCorrelation between Nocturia and Sleep: A Questionnaire Based Analysis
www.kjurology.org DOI:10.4111/kju.2010.51.11.757 Voiding Dysfunction Correlation between Nocturia and Sleep: A Questionnaire Based Analysis Seok Seon Yoo, Bong Suk Shim, Dong Hyeon Lee 1, Hyang Woon Lee
More informationRelationship between Urological Disease and Inferior Vena Cava Reflux on Color Doppler Ultrasonography
LUTS (2011) 3, 94 98 ORIGINAL ARTICLE Relationship between Urological Disease and Inferior Vena Cava Reflux on Color Doppler Ultrasonography Kimio SUGAYA, 1,2 Eiri MATSUMURA, 3 Shinsuke TASAKI, 3 Ryu KIMURA,
More informationPresented by Grace Smith CNC Latrobe Regional Hospital Continence Clinic
Presented by Grace Smith CNC Latrobe Regional Hospital Continence Clinic Better understand the true effects of aging on the lower urinary tract / bladder Consider other factors that may contribute to urinary
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationTzu Chi Medical Journal
Tzu Chi Medical Journal 25 (2013) 98e102 Contents lists available at SciVerse ScienceDirect Tzu Chi Medical Journal journal homepage: www.tzuchimedjnl.com Original Article First-line antimuscarinic monotherapy
More informationParkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute
Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease 2 nd most common neurodegenerative disorder Peak age at onset is 60 years
More informationOptimal bladder diary duration for patients with suprapontine neurogenic lower urinary tract dysfunction
ORIGINAL ARTICLE Vol. 42 (4): 766-772, July - August, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0292 Optimal bladder diary duration for patients with suprapontine neurogenic lower urinary tract dysfunction
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 4: , 2012
1112 Usefulness of total bladder capacity and post void residual urine volume as a predictor of detrusor overactivity with impaired contractility in stroke patients SANG HYUB LEE, JOONG GEUN LEE, GYEONG
More informationEvaluation and Treatment of Lower Urinary Tract Symptoms in Older Men
Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men P. Abrams,*, C. Chapple, S. Khoury, C. Roehrborn and J. de la Rosette on behalf of the International Scientific Committee and members
More informationManagement of male LUTS in general practice
17 Management of male LUTS in general practice MARK J. SPEAKMAN AND FAITH MCMEEKIN The initial management of lower urinary tract symptoms in men is usually carried out in primary care. The authors explain
More informationEffect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic Study
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.12.840 Voiding Dysfunction/Female Urology Effect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic
More informationOriginal Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:
Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationOctober 6, 2015 AGS/NIA U13 Conference Bethesda, Maryland Treating Sleep as a Geriatric Syndrome: Nocturia
October 6, 2015 AGS/NIA U13 Conference Bethesda, Maryland Treating Sleep as a Geriatric Syndrome: Nocturia Donald L. Bliwise, Ph.D. Professor of Neurology Emory University School of Medicine Atlanta, Georgia
More informationDr. Aso Urinary Symptoms
Haematuria The presence of blood in the urine (haematuria) is always abnormal and may be the only indication of pathology in the urinary tract. False positive stick tests and the discolored urine caused
More informationWho Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?
LUTS (2013) 5, 145 149 ORIGINAL ARTICLE Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign rostatic Hyperplasia? Jun OBATA, Kazuhiro
More informationLUTS in the modern era. Dr Jon Rees Tyntesfield Medical Group
LUTS in the modern era Dr Jon Rees Tyntesfield Medical Group In the past! Man with urinary symptoms = PROSTATISM Prostatism = TURP TURP unsuccessful = REDO TURP Redo TURP unsuccessful = can t help you!
More informationDiane K. Newman DNP, ANP-BC, PCB-PMD, FAAN
Diane K. Newman DNP, ANP-BC, PCB-PMD, FAAN Diane K. Newman, DNP is a Biofeedback Certified Continence Specialist. With over 35-years experience, she is an expert in the assessment and management of pelvic-floor
More informationIntermittent Catheterisation What do we need to know? Workshop
Intermittent Catheterisation What do we need to know? Workshop Hanny Cobussen-Boekhorst, PhD, MANP, RN Continence and Urostomy care Radboud University Medical Center Department of Urology Nijmegen, The
More informationNew Aspects of the Classification of Nocturia
New Aspects of the Classification of Nocturia Jeffrey P. Weiss, MD, Aaron C. Weinberg, and Jerry G. Blaivas, MD Corresponding author Jeffrey P. Weiss, MD Department of Urology, Weill Medical College of
More informationPolicy for Prostatism/Lower Urinary Tract Symptoms in men
NHS Halton Clinical Commissioning Group NHS Liverpool Clinical Commissioning Group NHS St Helens Clinical Commissioning Group NHS South Sefton Clinical Commissioning Group NHS Southport and Formby Clinical
More informationEffect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder
www.kjurology.org DOI:10.4111/kju.2011.52.6.396 Voiding Dysfunction Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder Young Kook Han, Won Ki Lee, Seong Ho Lee, Dae
More informationCross-sectional and longitudinal studies on interaction between bladder compliance and outflow obstruction in men with benign prostatic hyperplasia
Asian J Androl 2007; 9 (1): 51 56 DOI: 10.1111/j.1745-7262.2007.00221.x www.asiaandro.com. Original Article. Cross-sectional and longitudinal studies on interaction between bladder compliance and outflow
More informationOveractive Bladder beyond antimuscarinics
Overactive Bladder beyond antimuscarinics Marcus Drake Bristol Urological Institute Conflicts of interest; Allergan, AMS, Astellas, Ferring, Pfizer Getting the diagnosis right Improving treatment Improving
More information(2) Assistant Professor of Pathology
The Association between (Serum prostatic specific antigen and Dihydrotestosterone) and Efficacy of Solifenacin Therapy for Benign prostatic hypertrophy Patient in Salahalddin (1) Mohammed Mohsin Abdul-Aziz,
More informationOveractive Bladder in Clinical Practice
Overactive Bladder in Clinical Practice Alan J. Wein Christopher Chapple Overactive Bladder in Clinical Practice Authors Alan J. Wein Division of Urology University of Pennsylvania Health System Philadelphia
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationEvaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Evaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients N. Narayanamoorthy,
More informationAbstract. Key words Trial without catheter, Acute urinary retention, Benign prostatic hyperplasia, Introduction
The role of sustained-released alfuzosin in the treatment of acute urinary retention Mohamed Fawzi Ahmed. Department of Surgery, Ninevah College of Medicine, University of Mosul. Abstract To see whether
More informationNocturia and Urgency in Overactive Bladder. Reviews 1 Urgency: the key to defining the overactive bladder. Paul Abrams
BJU International Official journal of the British Association of Urological Surgeons and the Urological Society of Australasia September 25 - Vol. 96 Issue s1 Page 1-45 Nocturia and Urgency in Overactive
More informationTable 1. International Consultation on Incontinence recommendations for frail older adults
Table 1. International Consultation on Incontinence recommendations for frail older adults Clinicians need to assess and manage co-existing co morbid conditions which are known to have an impact on continence
More informationOverview. Surviving shift work. What is the circadian rhythm? Components of a Generic Biological Timing System 31/10/2017
Overview Surviving shift work Dr Claire M. Ellender Respiratory and Sleep Physician Princess Alexandra Hospital Conflicts nil relevant Circadian rhythm Impacts of shift work on health Case example Circadian
More informationAs man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG Beaconsfield Medical Practice, Brighton As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder
More informationVoiding Dysfunction. Jae Hyun Bae, Sun Ouck Kim 1, Eun Sang Yoo 2, Kyung Hyun Moon 3, Yoon Soo Kyung 4, Hyung Jee Kim 4
www.kjurology.org DOI:10.4111/kju.2011.52.4.274 Voiding Dysfunction Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Storage Symptoms:
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationA recent randomized controlled trial of a SMP for patients with LUTS reported positive results. In the group of patients who used the
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Lower Urinary Tract SELF-MANAGEMENT OF LUTS AND FREQUENCY-VOLUME CHART MEASURES YAP et al. BJUI BJU INTERNATIONAL The impact of self-management of lower urinary
More informationPrimary Care Evaluation and Treatment of Men With Lower Urinary Tract Symptoms
Primary Care Evaluation and Treatment of Men With Lower Urinary Tract Symptoms Nathan Hale, DO Kellen Choi, DO Joshua Lohri, DO From the Department of Urology at the Charleston Area Medical Center in West
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationTamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
J. Acad. Indus. Res. Vol. 1(11) April 2013 679 RESEARCH MANUSCRIPT ISSN: 2278-5213 Tamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
More informationClinical guidelines for nocturia
International Journal of Urology (2010) 17, 397 409 doi: 10.1111/j.1442-2042.2010.02527.x Guidelinesiju_2527 397..409 Clinical guidelines for nocturia The Committee for Establishment of the Clinical Guidelines
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationTEST BANK FOR GERONTOLOGICAL NURSING 3RD EDITION BY TABLOSKI Chapter 08
Link full download: http://testbankair.com/download/test-bank-forgerontological-nursing-3rd-edition-by-tabloski/ TEST BANK FOR GERONTOLOGICAL NURSING 3RD EDITION BY TABLOSKI Chapter 08 View Sample Question
More informationPrevalence of Lower Urinary Tract Symptoms in Indigenous and Non-indigenous Women in Eastern Taiwan
Volume 109 Number 3 March 2010 Hepatitis C virus therapy Psychiatric morbidity in HIV-infected male prisoners Intravascular large B cell lymphoma in Taiwan Chinese incontinentia pigmenti NEMO gene mutations
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationMen s Lower Urinary Tract Symptoms Are Also Mental and Physical Sufferings for Their Spouses
J Korean Med Sci 2009; 24: 320-5 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.2.320 Copyright The Korean Academy of Medical Sciences Men s Lower Urinary Tract Symptoms Are Also Mental and Physical Sufferings
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationPrevalence of the Overactive Bladder Syndrome byapplying the International Continence Society Definition
European Urology European Urology 48 (2005) 622 627 Female Urology ^ Incontinence Prevalence of the Overactive Bladder Syndrome byapplying the International Continence Society Definition Christian Temml
More informationLong-term persistence with mirabegron in a real-world clinical setting
International Journal of Urology (2018) 25, 501--506 doi: 10.1111/iju.13558 Original Article: Clinical Investigation Long-term persistence with in a real-world clinical setting Naoki Wada, Masaki Watanabe,
More informationNocturia, Insomnia Symptoms and Mortality among Older Men: The Health, Aging and Body Composition Study
pii: jc-00243-15 http://dx.doi.org/10.5664/jcsm.5870 SCIENTIFIC INVESTIGATIONS Nocturia, Insomnia Symptoms and Mortality among Older Men: The Health, Aging and Body Composition Study Yohannes W. Endeshaw,
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationOveractive bladder can result from one or more of the following causes:
Overactive bladder can affect people of any age; however, it is more common in older people. Effective treatments are available and seeing your doctor for symptoms of overactive bladder often results in
More informationSilodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007
More information